• The most common adverse events related to the treatment were fatigue (92%) and anemia (58%)• A positive outcome was indicated by a 58% radiographic progression-free survival (rPFS) rate at the 6-month mark• Out of the nine patients whose HRR gene status was evaluated, one patient exhibited a BRCA2 alteration (with an rPFS of 11.8 months), and another patient had a CDK12 alteration (with an rPFS of 3.1 months). The gene discussed is BRCA2; the disease is anemia.